Literature DB >> 27056247

Mortality and survival of lung cancer in Denmark: Results from the Danish Lung Cancer Group 2000-2012.

Erik Jakobsen1,2, Torben Riis Rasmussen3, Anders Green2,4.   

Abstract

Background In the 1990s outcomes in Danish lung cancer patients were poor compared with the other Nordic countries. The five-year survival was only about 5%, only 10% of patients were operated on and less than 60% received active surgical or oncologic treatment. This paper describes trends in mortality and survival of lung cancer in Denmark from 2000 to 2012. Methods The study population comprised 52 435 patients with a diagnosis of cancer of the trachea and the lung, primarily ascertained from the Danish Lung Cancer Register and grouped into three cohorts by year of diagnosis. The outcome measures covered the first year as well as the first full five-year period after diagnosis and comprised absolute mortality rate (per 100 patient years), absolute survival, and the relative survival. All outcomes were estimated for the overall patient population as well as after stratification by covariates. Results Overall, the mortality rates have declined significantly over time from 117 per 100 patient years to 88 for the one-year mortality and from 75 to 65 for the five-year mortality rates, respectively. With the exception of patients with advanced stage, declining mortality was observed for all strata by gender, comorbidity, stage and surgery status and was accompanied by corresponding improvements in both absolute and relative survival. Conclusions The mortality has been significantly declining and the prognosis correspondingly improving in lung cancer in Denmark since the turn of the millennium. As of today, survival after lung cancer in Denmark is probably in line with the international standard. Based on our results we recommend introducing mortality indicators based on all-cause mortality within the patient population in international benchmarking studies as comparisons based on cancer-specific mortality relative to the total general population may be misleading when interpreted in the context of outcomes and quality of care.

Entities:  

Mesh:

Year:  2016        PMID: 27056247     DOI: 10.3109/0284186X.2016.1150608

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  16 in total

1.  Cezanne contributes to cancer progression by playing a key role in the deubiquitination of IGF-1R.

Authors:  Xiaowei Chen; Zhaofei Pang; Yu Wang; Linhai Zhu; Jichang Liu; Jiajun Du
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Identification of differentially expressed protein-coding genes in lung adenocarcinomas.

Authors:  Luyao Wang; Shicheng Li; Yuanyong Wang; Zhenxue Tang; Chaolong Liu; Wenjie Jiao; Jia Liu
Journal:  Exp Ther Med       Date:  2019-12-06       Impact factor: 2.447

3.  A widening longevity gap between people with schizophrenia and general population: A literature review and call for action.

Authors:  Ellen E Lee; Jinyuan Liu; Xin Tu; Barton W Palmer; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Res       Date:  2017-09-28       Impact factor: 4.939

4.  Cancers Preceding Parkinson's Disease after Adjustment for Bias in a Danish Population-Based Case-Control Study.

Authors:  Xin Cui; Zeyan Liew; Johnni Hansen; Pei-Chen Lee; Onyebuchi A Arah; Beate Ritz
Journal:  Neuroepidemiology       Date:  2019-01-18       Impact factor: 3.282

5.  EGFR mutation, smoking, and gender in advanced lung adenocarcinoma.

Authors:  Chien-Hua Tseng; Chun-Ju Chiang; Jeng-Sen Tseng; Tsung-Ying Yang; Kuo-Hsuan Hsu; Kun-Chieh Chen; Chih-Liang Wang; Chih-Yi Chen; Sang-Hue Yen; Chun-Ming Tsai; Ming-Shyan Huang; Chao-Chi Ho; Chong-Jen Yu; Ying-Huang Tsai; Jin-Shing Chen; Teh-Ying Chou; Ming-Hsun Tsai; Hsuan-Yu Chen; Kang-Yi Su; Jeremy J W Chen; Huei-Wen Chen; Sung-Liang Yu; Tsang-Wu Liu; Gee-Chen Chang
Journal:  Oncotarget       Date:  2017-10-12

6.  Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients.

Authors:  Henrik Møller; Victoria H Coupland; Daniela Tataru; Michael D Peake; Anders Mellemgaard; Thomas Round; David R Baldwin; Matthew E J Callister; Erik Jakobsen; Peter Vedsted; Richard Sullivan; James Spicer
Journal:  Thorax       Date:  2018-03-06       Impact factor: 9.139

7.  AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival.

Authors:  Katja Kemp Jacobsen; Jakob Sidenius Johansen; Anders Mellemgaard; Stig Egil Bojesen
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

8.  miR-21 promotes non-small cell lung cancer cells growth by regulating fatty acid metabolism.

Authors:  Kewei Ni; Dimin Wang; Heyun Xu; Fuyang Mei; Changhao Wu; Zhifang Liu; Bing Zhou
Journal:  Cancer Cell Int       Date:  2019-08-23       Impact factor: 5.722

9.  Patient perspectives and experience on the diagnostic pathway of lung cancer: A qualitative study.

Authors:  Helle Marie Christensen; Lotte Huniche
Journal:  SAGE Open Med       Date:  2020-05-06

10.  Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011-2016.

Authors:  Krisztina Bogos; Zoltan Kiss; Lilla Tamási; Gyula Ostoros; Veronika Müller; László Urbán; Nóra Bittner; Veronika Sárosi; Aladár Vastag; Zoltán Polányi; Zsófia Nagy-Erdei; Andrea Daniel; Zoltán Vokó; Balázs Nagy; Krisztián Horváth; György Rokszin; Zsolt Abonyi-Tóth; Zsófia Barcza; Gabriella Gálffy; Judit Moldvay
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.